Analyst Ratings For Neurocrine Biosciences (NASDAQ:NBIX)
Today, Needham & Company LLC reiterated its Buy rating on Neurocrine Biosciences (NASDAQ:NBIX) with a price target of $110.00.
Some recent analyst ratings include
- 2/22/2018-Needham & Company LLC Reiterated Rating of Buy .
- 2/14/2018-Barclays Reiterated Rating of Overweight.
- On 2/15/2018 Gary A Lyons, Director, sold 5,000 with an average share price of $84.67 per share and the total transaction amounting to $423,350.00.
- On 2/12/2018 Dimitri E Grigoriadis, Insider, sold 86,368 with an average share price of $78.32 per share and the total transaction amounting to $6,764,341.76.
- On 2/9/2018 Dimitri E Grigoriadis, Insider, sold 71,775 with an average share price of $77.98 per share and the total transaction amounting to $5,597,014.50.
- On 2/6/2018 Kevin Charles Gorman, CEO, sold 105,983 with an average share price of $80.25 per share and the total transaction amounting to $8,505,135.75.
- On 2/5/2018 Gary A Lyons, Director, sold 5,000 with an average share price of $83.08 per share and the total transaction amounting to $415,400.00.
- On 2/5/2018 Haig P Bozigian, Insider, sold 2,262 with an average share price of $83.10 per share and the total transaction amounting to $187,972.20.
- On 1/24/2018 William H Rastetter, Director, sold 9,500 with an average share price of $90.00 per share and the total transaction amounting to $855,000.00.
Recent Trading Activity for Neurocrine Biosciences (NASDAQ:NBIX)
Shares of Neurocrine Biosciences closed the previous trading session at 85.54 up +0.70 0.83% with 85.63999938964844 shares trading hands.